Table 3.

Incidence of cross sensitivity to NSAIDs among patients with aspirin induced asthma

Trial	Study design	Age (years)	Study population	Authors' definition of positive response	Maximum challenge dose (mg)	Subjects tested	Positive outcome	Incidence (%)	Sensitivity previously proved by challenge
Ibuprofen:
Chafee and Settipane 197428	Double blind, placebo controlled	16-60	Allergy and clinical immunology department	Reduction in peak expiratory flow > 15% (positive reactions ranged from 19-68%)	300	18	18	100	Yes
Szczeklik et al 19771	Double blind, placebo controlled	16-68	Allergy and clinical immunology department	Reduction in peak expiratory flow 16-25% and clinical symptoms of bronchial obstruction or reduction in in peak expiratory flow > 25% with no symptoms	400	31	30	97	Yes
Total (95% CI)*	—	Not available	—	—	Not available	—	—	98 (90 to 100)†	—
Naproxen:
Szczeklik et al 10771	Double blind, placebo controlled	16-68	Allergy and clinical immunology department	Reduction in peak expiratory flow 16-25% and clinical symptoms of bronchial obstruction or reduction in peak expiratory flow > 25% with no symptoms	100	11	11	100	Yes
Falliers 197329	Double blind, placebo controlled	Mean 39	Allergy and clinical immunology department	Reduction in peak expiratory flow > 20% up to four hours after dose	80	11	11	100	Yes
Total (95% CI)*	—	—	—	—	Not available	—	—	100 (83 to 100)†	—
Diclofenac:
Szczeklik et al 19771	Double blind, placebo controlled	16-68	Allergy and clinical immunology department	Reduction in peak expiratory flow 16-25% and clinical symptoms of bronchial obstruction or reduction in peak expiratory flow > 25% with no symptoms	40	14	12	86	Yes
Falliers 197329	Double blind, placebo controlled	Mean 39	Allergy and clinical immunology department	Reduction in peak expiratory flow > 20% up to four hours after dose	25	11	11	100	Yes
Total (95% CI)*	—	Not available	—	—	Not available	—	—	93 (76 to 100)†	—

^*Calculated from pooling incidence rate in individual studies.

^†Upper bound truncated at 100.